nodes	percent_of_prediction	percent_of_DWPC	metapath
Levonorgestrel—CYP3A4—bone cancer	0.771	1	CbGaD
Levonorgestrel—ESR1—LKB1 signaling events—ETV4—bone cancer	0.0036	0.0418	CbGpPWpGaD
Levonorgestrel—CYP19A1—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00358	0.0415	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling events mediated by HDAC Class II—BCOR—bone cancer	0.00354	0.0412	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear beta catenin signaling and target gene transcription—T—bone cancer	0.00284	0.033	CbGpPWpGaD
Levonorgestrel—PGR—Nuclear Receptors—NR1I2—bone cancer	0.0027	0.0313	CbGpPWpGaD
Levonorgestrel—Ethinyl Estradiol—NR1I2—bone cancer	0.00244	0.346	CrCbGaD
Levonorgestrel—PGR—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.00213	0.0248	CbGpPWpGaD
Levonorgestrel—AR—Nuclear Receptors—NR1I2—bone cancer	0.00205	0.0239	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—FEV—bone cancer	0.00196	0.0228	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling events mediated by HDAC Class II—TUBB2A—bone cancer	0.00168	0.0195	CbGpPWpGaD
Levonorgestrel—AR—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.00162	0.0189	CbGpPWpGaD
Levonorgestrel—ESR1—Nuclear Receptors—NR1I2—bone cancer	0.00158	0.0184	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metapathway biotransformation—CYP4V2—bone cancer	0.00154	0.0179	CbGpPWpGaD
Levonorgestrel—ESR1—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.00125	0.0145	CbGpPWpGaD
Levonorgestrel—PGR—Ovarian Infertility Genes—CDK4—bone cancer	0.00112	0.013	CbGpPWpGaD
Levonorgestrel—PGR—Generic Transcription Pathway—ZNF77—bone cancer	0.00109	0.0126	CbGpPWpGaD
Levonorgestrel—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00104	0.0121	CbGpPWpGaD
Levonorgestrel—Allylestrenol—CYP3A4—bone cancer	0.00104	0.147	CrCbGaD
Levonorgestrel—ESR1—Signaling mediated by p38-alpha and p38-beta—ATF1—bone cancer	0.00101	0.0118	CbGpPWpGaD
Levonorgestrel—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000982	0.0114	CbGpPWpGaD
Levonorgestrel—ESR1—Plasma membrane estrogen receptor signaling—GNA11—bone cancer	0.00096	0.0111	CbGpPWpGaD
Levonorgestrel—CYP19A1—Tryptophan metabolism—CYP3A4—bone cancer	0.000886	0.0103	CbGpPWpGaD
Levonorgestrel—ESR1—Estrogen Receptor Pathway—JUN—bone cancer	0.000871	0.0101	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—NDUFA12—bone cancer	0.000852	0.00989	CbGpPWpGaD
Levonorgestrel—ESR1—FOXM1 transcription factor network—CHEK2—bone cancer	0.000842	0.00978	CbGpPWpGaD
Levonorgestrel—AR—Generic Transcription Pathway—ZNF77—bone cancer	0.000828	0.00962	CbGpPWpGaD
Levonorgestrel—ESR1—Regulation of Telomerase—WT1—bone cancer	0.000823	0.00956	CbGpPWpGaD
Levonorgestrel—Etonogestrel—CYP3A4—bone cancer	0.000809	0.115	CrCbGaD
Levonorgestrel—ESR1—Estrogen signaling pathway—BRAF—bone cancer	0.000758	0.0088	CbGpPWpGaD
Levonorgestrel—CYP19A1—Ovarian Infertility Genes—CDK4—bone cancer	0.000735	0.00853	CbGpPWpGaD
Levonorgestrel—CYP19A1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000717	0.00832	CbGpPWpGaD
Levonorgestrel—ESR1—FOXM1 transcription factor network—BRCA2—bone cancer	0.000713	0.00829	CbGpPWpGaD
Levonorgestrel—CYP19A1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000707	0.00821	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—NT5C3A—bone cancer	0.000706	0.0082	CbGpPWpGaD
Levonorgestrel—ESR1—Plasma membrane estrogen receptor signaling—IGF1R—bone cancer	0.0007	0.00813	CbGpPWpGaD
Levonorgestrel—ESR1—Generic Transcription Pathway—ZNF77—bone cancer	0.000638	0.00741	CbGpPWpGaD
Levonorgestrel—CYP19A1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000581	0.00675	CbGpPWpGaD
Levonorgestrel—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000564	0.00655	CbGpPWpGaD
Levonorgestrel—ESR1—Estrogen signaling pathway—JUN—bone cancer	0.000552	0.00641	CbGpPWpGaD
Levonorgestrel—AR—Notch-mediated HES/HEY network—RB1—bone cancer	0.000546	0.00634	CbGpPWpGaD
Levonorgestrel—ESR1—FOXM1 transcription factor network—CDK4—bone cancer	0.000529	0.00615	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—ZNF77—bone cancer	0.000524	0.00608	CbGpPWpGaD
Levonorgestrel—Danazol—CYP3A4—bone cancer	0.000521	0.0739	CrCbGaD
Levonorgestrel—Ethinyl Estradiol—CYP3A4—bone cancer	0.000482	0.0684	CrCbGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000468	0.00543	CbGpPWpGaD
Levonorgestrel—Norethindrone—CYP3A4—bone cancer	0.000464	0.0658	CrCbGaD
Levonorgestrel—ESR1—FOXM1 transcription factor network—RB1—bone cancer	0.00046	0.00534	CbGpPWpGaD
Levonorgestrel—ESR1—Plasma membrane estrogen receptor signaling—MMP2—bone cancer	0.00045	0.00523	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000449	0.00522	CbGpPWpGaD
Levonorgestrel—ESR1—FOXM1 transcription factor network—MMP2—bone cancer	0.000441	0.00513	CbGpPWpGaD
Levonorgestrel—Methyltestosterone—CYP3A4—bone cancer	0.00044	0.0625	CrCbGaD
Levonorgestrel—ESR1—Signaling mediated by p38-alpha and p38-beta—PTGS2—bone cancer	0.000438	0.00508	CbGpPWpGaD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000428	0.00497	CbGpPWpGaD
Levonorgestrel—ESR1—ATF-2 transcription factor network—PLAU—bone cancer	0.000427	0.00495	CbGpPWpGaD
Levonorgestrel—AR—FOXA1 transcription factor network—JUN—bone cancer	0.000426	0.00495	CbGpPWpGaD
Levonorgestrel—AR—Regulation of Androgen receptor activity—MDM2—bone cancer	0.000423	0.00491	CbGpPWpGaD
Levonorgestrel—PGR—Validated nuclear estrogen receptor alpha network—JUN—bone cancer	0.000415	0.00482	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—ATF1—bone cancer	0.000408	0.00474	CbGpPWpGaD
Levonorgestrel—CYP19A1—Tryptophan metabolism—MDM2—bone cancer	0.000407	0.00473	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear SMAD2/3 signaling—CDK4—bone cancer	0.000406	0.00472	CbGpPWpGaD
Levonorgestrel—ESR1—ATF-2 transcription factor network—CDK4—bone cancer	0.000403	0.00468	CbGpPWpGaD
Levonorgestrel—Breast disorder—Methotrexate—bone cancer	0.000399	0.00293	CcSEcCtD
Levonorgestrel—AR—Gene Expression—ZNF77—bone cancer	0.000399	0.00463	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000398	0.00462	CbGpPWpGaD
Levonorgestrel—Purpura—Doxorubicin—bone cancer	0.000397	0.00291	CcSEcCtD
Levonorgestrel—Oedema—Cisplatin—bone cancer	0.000396	0.0029	CcSEcCtD
Levonorgestrel—ESR1—Signaling mediated by p38-alpha and p38-beta—JUN—bone cancer	0.000394	0.00458	CbGpPWpGaD
Levonorgestrel—Infection—Cisplatin—bone cancer	0.000393	0.00288	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—CHEK2—bone cancer	0.000393	0.00456	CbGpPWpGaD
Levonorgestrel—Mood swings—Epirubicin—bone cancer	0.000392	0.00287	CcSEcCtD
Levonorgestrel—Nervous system disorder—Cisplatin—bone cancer	0.000388	0.00285	CcSEcCtD
Levonorgestrel—Skin disorder—Cisplatin—bone cancer	0.000384	0.00282	CcSEcCtD
Levonorgestrel—Pain in extremity—Doxorubicin—bone cancer	0.000383	0.00281	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Cisplatin—bone cancer	0.000383	0.00281	CcSEcCtD
Levonorgestrel—Asthma—Methotrexate—bone cancer	0.000382	0.0028	CcSEcCtD
Levonorgestrel—Dry skin—Epirubicin—bone cancer	0.000379	0.00278	CcSEcCtD
Levonorgestrel—Anorexia—Cisplatin—bone cancer	0.000377	0.00277	CcSEcCtD
Levonorgestrel—Migraine—Doxorubicin—bone cancer	0.000377	0.00276	CcSEcCtD
Levonorgestrel—Affect lability—Doxorubicin—bone cancer	0.000377	0.00276	CcSEcCtD
Levonorgestrel—Breast disorder—Epirubicin—bone cancer	0.000374	0.00274	CcSEcCtD
Levonorgestrel—ESR1—AP-1 transcription factor network—PLAU—bone cancer	0.000372	0.00432	CbGpPWpGaD
Levonorgestrel—PGR—Generic Transcription Pathway—NR1I2—bone cancer	0.000368	0.00428	CbGpPWpGaD
Levonorgestrel—AR—Regulation of Androgen receptor activity—JUN—bone cancer	0.000367	0.00427	CbGpPWpGaD
Levonorgestrel—Mood swings—Doxorubicin—bone cancer	0.000363	0.00266	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000362	0.00421	CbGpPWpGaD
Levonorgestrel—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000361	0.00264	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.00036	0.00419	CbGpPWpGaD
Levonorgestrel—Abdominal distension—Epirubicin—bone cancer	0.00036	0.00264	CcSEcCtD
Levonorgestrel—Influenza—Epirubicin—bone cancer	0.000357	0.00262	CcSEcCtD
Levonorgestrel—Asthma—Epirubicin—bone cancer	0.000357	0.00262	CcSEcCtD
Levonorgestrel—Dysuria—Methotrexate—bone cancer	0.000357	0.00262	CcSEcCtD
Levonorgestrel—Upper respiratory tract infection—Methotrexate—bone cancer	0.000355	0.0026	CcSEcCtD
Levonorgestrel—Dyspnoea—Cisplatin—bone cancer	0.000353	0.00259	CcSEcCtD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000352	0.00408	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—ATF1—bone cancer	0.000351	0.00408	CbGpPWpGaD
Levonorgestrel—Dry skin—Doxorubicin—bone cancer	0.000351	0.00257	CcSEcCtD
Levonorgestrel—ESR1—ATF-2 transcription factor network—RB1—bone cancer	0.000351	0.00407	CbGpPWpGaD
Levonorgestrel—Breast disorder—Doxorubicin—bone cancer	0.000346	0.00254	CcSEcCtD
Levonorgestrel—Decreased appetite—Cisplatin—bone cancer	0.000344	0.00252	CcSEcCtD
Levonorgestrel—Bronchitis—Epirubicin—bone cancer	0.000344	0.00252	CcSEcCtD
Levonorgestrel—Pneumonia—Methotrexate—bone cancer	0.000343	0.00251	CcSEcCtD
Levonorgestrel—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—bone cancer	0.000342	0.00397	CbGpPWpGaD
Levonorgestrel—Gastrointestinal disorder—Cisplatin—bone cancer	0.000342	0.00251	CcSEcCtD
Levonorgestrel—Infestation NOS—Methotrexate—bone cancer	0.000341	0.0025	CcSEcCtD
Levonorgestrel—Infestation—Methotrexate—bone cancer	0.000341	0.0025	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—TGFBR2—bone cancer	0.00034	0.00395	CbGpPWpGaD
Levonorgestrel—Depression—Methotrexate—bone cancer	0.00034	0.00249	CcSEcCtD
Levonorgestrel—Pain—Cisplatin—bone cancer	0.000339	0.00248	CcSEcCtD
Levonorgestrel—ESR1—Plasma membrane estrogen receptor signaling—MMP9—bone cancer	0.000338	0.00393	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—CHEK2—bone cancer	0.000338	0.00392	CbGpPWpGaD
Levonorgestrel—ESR1—ATF-2 transcription factor network—MMP2—bone cancer	0.000336	0.00391	CbGpPWpGaD
Levonorgestrel—Dysuria—Epirubicin—bone cancer	0.000334	0.00245	CcSEcCtD
Levonorgestrel—Abdominal distension—Doxorubicin—bone cancer	0.000333	0.00244	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—BRCA2—bone cancer	0.000333	0.00386	CbGpPWpGaD
Levonorgestrel—Upper respiratory tract infection—Epirubicin—bone cancer	0.000332	0.00244	CcSEcCtD
Levonorgestrel—Hydrocortisone—CYP3A4—bone cancer	0.000332	0.0471	CrCbGaD
Levonorgestrel—Influenza—Doxorubicin—bone cancer	0.000331	0.00243	CcSEcCtD
Levonorgestrel—Asthma—Doxorubicin—bone cancer	0.000331	0.00243	CcSEcCtD
Levonorgestrel—Pollakiuria—Epirubicin—bone cancer	0.00033	0.00242	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.00033	0.00383	CbGpPWpGaD
Levonorgestrel—ESR1—FOXA1 transcription factor network—JUN—bone cancer	0.000328	0.00382	CbGpPWpGaD
Levonorgestrel—AR—Androgen receptor signaling pathway—RB1—bone cancer	0.000328	0.0038	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000325	0.00378	CbGpPWpGaD
Levonorgestrel—Weight increased—Epirubicin—bone cancer	0.000325	0.00239	CcSEcCtD
Levonorgestrel—Weight decreased—Epirubicin—bone cancer	0.000323	0.00237	CcSEcCtD
Levonorgestrel—Pneumonia—Epirubicin—bone cancer	0.000321	0.00235	CcSEcCtD
Levonorgestrel—Infestation—Epirubicin—bone cancer	0.000319	0.00234	CcSEcCtD
Levonorgestrel—Infestation NOS—Epirubicin—bone cancer	0.000319	0.00234	CcSEcCtD
Levonorgestrel—Bronchitis—Doxorubicin—bone cancer	0.000318	0.00233	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—ATF1—bone cancer	0.000314	0.00365	CbGpPWpGaD
Levonorgestrel—Body temperature increased—Cisplatin—bone cancer	0.000313	0.00229	CcSEcCtD
Levonorgestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—CDK4—bone cancer	0.000313	0.00363	CbGpPWpGaD
Levonorgestrel—Urinary tract infection—Epirubicin—bone cancer	0.00031	0.00227	CcSEcCtD
Levonorgestrel—Dysuria—Doxorubicin—bone cancer	0.000309	0.00227	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—ENO2—bone cancer	0.000309	0.00359	CbGpPWpGaD
Levonorgestrel—CYP19A1—Biological oxidations—CYP3A4—bone cancer	0.000309	0.00358	CbGpPWpGaD
Levonorgestrel—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000307	0.00225	CcSEcCtD
Levonorgestrel—Haemoglobin—Methotrexate—bone cancer	0.000307	0.00225	CcSEcCtD
Levonorgestrel—ESR1—Gene Expression—ZNF77—bone cancer	0.000307	0.00357	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000306	0.00356	CbGpPWpGaD
Levonorgestrel—Haemorrhage—Methotrexate—bone cancer	0.000306	0.00224	CcSEcCtD
Levonorgestrel—Pollakiuria—Doxorubicin—bone cancer	0.000306	0.00224	CcSEcCtD
Levonorgestrel—CYP19A1—Metapathway biotransformation—CYP3A4—bone cancer	0.000304	0.00354	CbGpPWpGaD
Levonorgestrel—Pharyngitis—Methotrexate—bone cancer	0.000303	0.00223	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—KIT—bone cancer	0.000303	0.00352	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—CHEK2—bone cancer	0.000302	0.00351	CbGpPWpGaD
Levonorgestrel—Urinary tract disorder—Methotrexate—bone cancer	0.000302	0.00221	CcSEcCtD
Levonorgestrel—Weight increased—Doxorubicin—bone cancer	0.000301	0.00221	CcSEcCtD
Levonorgestrel—Urethral disorder—Methotrexate—bone cancer	0.0003	0.0022	CcSEcCtD
Levonorgestrel—Weight decreased—Doxorubicin—bone cancer	0.000299	0.00219	CcSEcCtD
Levonorgestrel—Sinusitis—Epirubicin—bone cancer	0.000299	0.00219	CcSEcCtD
Levonorgestrel—Pneumonia—Doxorubicin—bone cancer	0.000297	0.00218	CcSEcCtD
Levonorgestrel—Infestation NOS—Doxorubicin—bone cancer	0.000295	0.00216	CcSEcCtD
Levonorgestrel—Infestation—Doxorubicin—bone cancer	0.000295	0.00216	CcSEcCtD
Levonorgestrel—Visual impairment—Methotrexate—bone cancer	0.000295	0.00216	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—TGFBR2—bone cancer	0.000293	0.0034	CbGpPWpGaD
Levonorgestrel—Hypersensitivity—Cisplatin—bone cancer	0.000292	0.00214	CcSEcCtD
Levonorgestrel—Erythema multiforme—Methotrexate—bone cancer	0.000289	0.00212	CcSEcCtD
Levonorgestrel—Haemoglobin—Epirubicin—bone cancer	0.000288	0.00211	CcSEcCtD
Levonorgestrel—Rhinitis—Epirubicin—bone cancer	0.000287	0.0021	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—DHFR—bone cancer	0.000287	0.00333	CbGpPWpGaD
Levonorgestrel—Urinary tract infection—Doxorubicin—bone cancer	0.000287	0.0021	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—BRCA2—bone cancer	0.000286	0.00333	CbGpPWpGaD
Levonorgestrel—Haemorrhage—Epirubicin—bone cancer	0.000286	0.0021	CcSEcCtD
Levonorgestrel—Eye disorder—Methotrexate—bone cancer	0.000286	0.0021	CcSEcCtD
Levonorgestrel—Hypoaesthesia—Epirubicin—bone cancer	0.000285	0.00209	CcSEcCtD
Levonorgestrel—Asthenia—Cisplatin—bone cancer	0.000284	0.00208	CcSEcCtD
Levonorgestrel—Pharyngitis—Epirubicin—bone cancer	0.000284	0.00208	CcSEcCtD
Levonorgestrel—Cardiac disorder—Methotrexate—bone cancer	0.000284	0.00208	CcSEcCtD
Levonorgestrel—Urinary tract disorder—Epirubicin—bone cancer	0.000283	0.00207	CcSEcCtD
Levonorgestrel—Connective tissue disorder—Epirubicin—bone cancer	0.000281	0.00206	CcSEcCtD
Levonorgestrel—Urethral disorder—Epirubicin—bone cancer	0.00028	0.00206	CcSEcCtD
Levonorgestrel—AR—Generic Transcription Pathway—NR1I2—bone cancer	0.00028	0.00326	CbGpPWpGaD
Levonorgestrel—AR—Androgen receptor signaling pathway—MDM2—bone cancer	0.000279	0.00324	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000279	0.00324	CbGpPWpGaD
Levonorgestrel—Sinusitis—Doxorubicin—bone cancer	0.000277	0.00203	CcSEcCtD
Levonorgestrel—Immune system disorder—Methotrexate—bone cancer	0.000276	0.00203	CcSEcCtD
Levonorgestrel—Visual impairment—Epirubicin—bone cancer	0.000276	0.00202	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000276	0.0032	CbGpPWpGaD
Levonorgestrel—Mediastinal disorder—Methotrexate—bone cancer	0.000276	0.00202	CcSEcCtD
Levonorgestrel—Diarrhoea—Cisplatin—bone cancer	0.000271	0.00199	CcSEcCtD
Levonorgestrel—Erythema multiforme—Epirubicin—bone cancer	0.000271	0.00198	CcSEcCtD
Levonorgestrel—Alopecia—Methotrexate—bone cancer	0.00027	0.00198	CcSEcCtD
Levonorgestrel—Progesterone—CYP3A4—bone cancer	0.00027	0.0383	CrCbGaD
Levonorgestrel—SRD5A1—Metabolism—GNA11—bone cancer	0.000268	0.00311	CbGpPWpGaD
Levonorgestrel—Mental disorder—Methotrexate—bone cancer	0.000268	0.00196	CcSEcCtD
Levonorgestrel—Eye disorder—Epirubicin—bone cancer	0.000267	0.00196	CcSEcCtD
Levonorgestrel—Erythema—Methotrexate—bone cancer	0.000266	0.00195	CcSEcCtD
Levonorgestrel—Malnutrition—Methotrexate—bone cancer	0.000266	0.00195	CcSEcCtD
Levonorgestrel—Haemoglobin—Doxorubicin—bone cancer	0.000266	0.00195	CcSEcCtD
Levonorgestrel—Cardiac disorder—Epirubicin—bone cancer	0.000266	0.00195	CcSEcCtD
Levonorgestrel—Rhinitis—Doxorubicin—bone cancer	0.000265	0.00195	CcSEcCtD
Levonorgestrel—Haemorrhage—Doxorubicin—bone cancer	0.000265	0.00194	CcSEcCtD
Levonorgestrel—AR—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—bone cancer	0.000264	0.00307	CbGpPWpGaD
Levonorgestrel—CYP19A1—Biological oxidations—GSTP1—bone cancer	0.000264	0.00307	CbGpPWpGaD
Levonorgestrel—Hypoaesthesia—Doxorubicin—bone cancer	0.000263	0.00193	CcSEcCtD
Levonorgestrel—Pharyngitis—Doxorubicin—bone cancer	0.000263	0.00193	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—TGFBR2—bone cancer	0.000262	0.00305	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear SMAD2/3 signaling—JUN—bone cancer	0.000262	0.00304	CbGpPWpGaD
Levonorgestrel—Urinary tract disorder—Doxorubicin—bone cancer	0.000261	0.00192	CcSEcCtD
Levonorgestrel—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—bone cancer	0.00026	0.00302	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metapathway biotransformation—GSTP1—bone cancer	0.00026	0.00302	CbGpPWpGaD
Levonorgestrel—Connective tissue disorder—Doxorubicin—bone cancer	0.00026	0.00191	CcSEcCtD
Levonorgestrel—ESR1—ATF-2 transcription factor network—JUN—bone cancer	0.00026	0.00302	CbGpPWpGaD
Levonorgestrel—Urethral disorder—Doxorubicin—bone cancer	0.00026	0.0019	CcSEcCtD
Levonorgestrel—Immune system disorder—Epirubicin—bone cancer	0.000258	0.0019	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Epirubicin—bone cancer	0.000258	0.00189	CcSEcCtD
Levonorgestrel—Back pain—Methotrexate—bone cancer	0.000257	0.00189	CcSEcCtD
Levonorgestrel—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—bone cancer	0.000257	0.00299	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—BRCA2—bone cancer	0.000256	0.00298	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—FUS—bone cancer	0.000256	0.00297	CbGpPWpGaD
Levonorgestrel—Arrhythmia—Epirubicin—bone cancer	0.000256	0.00187	CcSEcCtD
Levonorgestrel—Testosterone—CYP3A4—bone cancer	0.000255	0.0362	CrCbGaD
Levonorgestrel—Visual impairment—Doxorubicin—bone cancer	0.000255	0.00187	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000254	0.00295	CbGpPWpGaD
Levonorgestrel—Alopecia—Epirubicin—bone cancer	0.000253	0.00185	CcSEcCtD
Levonorgestrel—Vomiting—Cisplatin—bone cancer	0.000252	0.00185	CcSEcCtD
Levonorgestrel—Mental disorder—Epirubicin—bone cancer	0.000251	0.00184	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000251	0.00291	CbGpPWpGaD
Levonorgestrel—Erythema multiforme—Doxorubicin—bone cancer	0.00025	0.00184	CcSEcCtD
Levonorgestrel—Rash—Cisplatin—bone cancer	0.00025	0.00183	CcSEcCtD
Levonorgestrel—Dermatitis—Cisplatin—bone cancer	0.000249	0.00183	CcSEcCtD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.000249	0.0029	CbGpPWpGaD
Levonorgestrel—Malnutrition—Epirubicin—bone cancer	0.000249	0.00183	CcSEcCtD
Levonorgestrel—Erythema—Epirubicin—bone cancer	0.000249	0.00183	CcSEcCtD
Levonorgestrel—Eye disorder—Doxorubicin—bone cancer	0.000247	0.00181	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—CDK4—bone cancer	0.000247	0.00287	CbGpPWpGaD
Levonorgestrel—Anaemia—Methotrexate—bone cancer	0.000246	0.0018	CcSEcCtD
Levonorgestrel—Cardiac disorder—Doxorubicin—bone cancer	0.000246	0.0018	CcSEcCtD
Levonorgestrel—Flatulence—Epirubicin—bone cancer	0.000245	0.0018	CcSEcCtD
Levonorgestrel—Tension—Epirubicin—bone cancer	0.000244	0.00179	CcSEcCtD
Levonorgestrel—ESR1—Validated nuclear estrogen receptor alpha network—JUN—bone cancer	0.000243	0.00283	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—CYP3A4—bone cancer	0.000243	0.00282	CbGpPWpGaD
Levonorgestrel—AR—Androgen receptor signaling pathway—JUN—bone cancer	0.000243	0.00282	CbGpPWpGaD
Levonorgestrel—Nervousness—Epirubicin—bone cancer	0.000242	0.00177	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000242	0.00281	CbGpPWpGaD
Levonorgestrel—Back pain—Epirubicin—bone cancer	0.000241	0.00177	CcSEcCtD
Levonorgestrel—Muscle spasms—Epirubicin—bone cancer	0.000239	0.00176	CcSEcCtD
Levonorgestrel—Immune system disorder—Doxorubicin—bone cancer	0.000239	0.00175	CcSEcCtD
Levonorgestrel—Vertigo—Methotrexate—bone cancer	0.000239	0.00175	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—MDM2—bone cancer	0.000239	0.00277	CbGpPWpGaD
Levonorgestrel—Mediastinal disorder—Doxorubicin—bone cancer	0.000239	0.00175	CcSEcCtD
Levonorgestrel—Arrhythmia—Doxorubicin—bone cancer	0.000237	0.00173	CcSEcCtD
Levonorgestrel—Nausea—Cisplatin—bone cancer	0.000235	0.00172	CcSEcCtD
Levonorgestrel—Alopecia—Doxorubicin—bone cancer	0.000234	0.00172	CcSEcCtD
Levonorgestrel—Cough—Methotrexate—bone cancer	0.000232	0.0017	CcSEcCtD
Levonorgestrel—Mental disorder—Doxorubicin—bone cancer	0.000232	0.0017	CcSEcCtD
Levonorgestrel—ESR1—Regulation of Telomerase—JUN—bone cancer	0.000232	0.00269	CbGpPWpGaD
Levonorgestrel—Erythema—Doxorubicin—bone cancer	0.00023	0.00169	CcSEcCtD
Levonorgestrel—Malnutrition—Doxorubicin—bone cancer	0.00023	0.00169	CcSEcCtD
Levonorgestrel—Anaemia—Epirubicin—bone cancer	0.00023	0.00169	CcSEcCtD
Levonorgestrel—Flatulence—Doxorubicin—bone cancer	0.000227	0.00167	CcSEcCtD
Levonorgestrel—Chest pain—Methotrexate—bone cancer	0.000227	0.00166	CcSEcCtD
Levonorgestrel—Myalgia—Methotrexate—bone cancer	0.000227	0.00166	CcSEcCtD
Levonorgestrel—ESR1—AP-1 transcription factor network—JUN—bone cancer	0.000227	0.00263	CbGpPWpGaD
Levonorgestrel—Tension—Doxorubicin—bone cancer	0.000226	0.00166	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000225	0.00165	CcSEcCtD
Levonorgestrel—Discomfort—Methotrexate—bone cancer	0.000224	0.00164	CcSEcCtD
Levonorgestrel—Nervousness—Doxorubicin—bone cancer	0.000224	0.00164	CcSEcCtD
Levonorgestrel—Vertigo—Epirubicin—bone cancer	0.000224	0.00164	CcSEcCtD
Levonorgestrel—Syncope—Epirubicin—bone cancer	0.000223	0.00164	CcSEcCtD
Levonorgestrel—Back pain—Doxorubicin—bone cancer	0.000223	0.00163	CcSEcCtD
Levonorgestrel—Muscle spasms—Doxorubicin—bone cancer	0.000222	0.00162	CcSEcCtD
Levonorgestrel—ESR1—LKB1 signaling events—TP53—bone cancer	0.000221	0.00257	CbGpPWpGaD
Levonorgestrel—ESR1—AP-1 transcription factor network—MMP9—bone cancer	0.00022	0.00256	CbGpPWpGaD
Levonorgestrel—Palpitations—Epirubicin—bone cancer	0.00022	0.00161	CcSEcCtD
Levonorgestrel—Loss of consciousness—Epirubicin—bone cancer	0.000219	0.00161	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—BRAF—bone cancer	0.000218	0.00254	CbGpPWpGaD
Levonorgestrel—Cough—Epirubicin—bone cancer	0.000217	0.00159	CcSEcCtD
Levonorgestrel—ESR1—Generic Transcription Pathway—NR1I2—bone cancer	0.000216	0.00251	CbGpPWpGaD
Levonorgestrel—Infection—Methotrexate—bone cancer	0.000216	0.00158	CcSEcCtD
Levonorgestrel—Hypertension—Epirubicin—bone cancer	0.000215	0.00158	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—RB1—bone cancer	0.000215	0.00249	CbGpPWpGaD
Levonorgestrel—Nervous system disorder—Methotrexate—bone cancer	0.000213	0.00156	CcSEcCtD
Levonorgestrel—Anaemia—Doxorubicin—bone cancer	0.000213	0.00156	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000212	0.00247	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—CDK4—bone cancer	0.000212	0.00247	CbGpPWpGaD
Levonorgestrel—Myalgia—Epirubicin—bone cancer	0.000212	0.00155	CcSEcCtD
Levonorgestrel—Chest pain—Epirubicin—bone cancer	0.000212	0.00155	CcSEcCtD
Levonorgestrel—Anxiety—Epirubicin—bone cancer	0.000211	0.00155	CcSEcCtD
Levonorgestrel—Skin disorder—Methotrexate—bone cancer	0.000211	0.00155	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000211	0.00154	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Methotrexate—bone cancer	0.00021	0.00154	CcSEcCtD
Levonorgestrel—Discomfort—Epirubicin—bone cancer	0.00021	0.00154	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—GSTP1—bone cancer	0.000208	0.00241	CbGpPWpGaD
Levonorgestrel—Vertigo—Doxorubicin—bone cancer	0.000207	0.00152	CcSEcCtD
Levonorgestrel—Anorexia—Methotrexate—bone cancer	0.000207	0.00152	CcSEcCtD
Levonorgestrel—Syncope—Doxorubicin—bone cancer	0.000207	0.00152	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.000204	0.00238	CbGpPWpGaD
Levonorgestrel—Palpitations—Doxorubicin—bone cancer	0.000204	0.00149	CcSEcCtD
Levonorgestrel—Oedema—Epirubicin—bone cancer	0.000203	0.00149	CcSEcCtD
Levonorgestrel—Loss of consciousness—Doxorubicin—bone cancer	0.000203	0.00149	CcSEcCtD
Levonorgestrel—Infection—Epirubicin—bone cancer	0.000202	0.00148	CcSEcCtD
Levonorgestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—JUN—bone cancer	0.000202	0.00234	CbGpPWpGaD
Levonorgestrel—Cough—Doxorubicin—bone cancer	0.000201	0.00147	CcSEcCtD
Levonorgestrel—Shock—Epirubicin—bone cancer	0.0002	0.00147	CcSEcCtD
Levonorgestrel—Nervous system disorder—Epirubicin—bone cancer	0.000199	0.00146	CcSEcCtD
Levonorgestrel—Hypertension—Doxorubicin—bone cancer	0.000199	0.00146	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000198	0.00145	CcSEcCtD
Levonorgestrel—Skin disorder—Epirubicin—bone cancer	0.000197	0.00145	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Epirubicin—bone cancer	0.000197	0.00144	CcSEcCtD
Levonorgestrel—Insomnia—Methotrexate—bone cancer	0.000196	0.00144	CcSEcCtD
Levonorgestrel—Myalgia—Doxorubicin—bone cancer	0.000196	0.00144	CcSEcCtD
Levonorgestrel—Chest pain—Doxorubicin—bone cancer	0.000196	0.00144	CcSEcCtD
Levonorgestrel—Anxiety—Doxorubicin—bone cancer	0.000196	0.00143	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000195	0.00143	CcSEcCtD
Levonorgestrel—AR—Gene Expression—FUS—bone cancer	0.000195	0.00226	CbGpPWpGaD
Levonorgestrel—Discomfort—Doxorubicin—bone cancer	0.000194	0.00142	CcSEcCtD
Levonorgestrel—Anorexia—Epirubicin—bone cancer	0.000194	0.00142	CcSEcCtD
Levonorgestrel—Dyspnoea—Methotrexate—bone cancer	0.000194	0.00142	CcSEcCtD
Levonorgestrel—Somnolence—Methotrexate—bone cancer	0.000193	0.00142	CcSEcCtD
Levonorgestrel—Dyspepsia—Methotrexate—bone cancer	0.000191	0.0014	CcSEcCtD
Levonorgestrel—AR—Androgen receptor signaling pathway—EGFR—bone cancer	0.000191	0.00222	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—CDK4—bone cancer	0.00019	0.00221	CbGpPWpGaD
Levonorgestrel—Decreased appetite—Methotrexate—bone cancer	0.000189	0.00138	CcSEcCtD
Levonorgestrel—Oedema—Doxorubicin—bone cancer	0.000188	0.00138	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—BRAF—bone cancer	0.000188	0.00218	CbGpPWpGaD
Levonorgestrel—Gastrointestinal disorder—Methotrexate—bone cancer	0.000188	0.00138	CcSEcCtD
Levonorgestrel—Fatigue—Methotrexate—bone cancer	0.000187	0.00137	CcSEcCtD
Levonorgestrel—Infection—Doxorubicin—bone cancer	0.000187	0.00137	CcSEcCtD
Levonorgestrel—Pain—Methotrexate—bone cancer	0.000186	0.00136	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000185	0.00136	CcSEcCtD
Levonorgestrel—Shock—Doxorubicin—bone cancer	0.000185	0.00136	CcSEcCtD
Levonorgestrel—CYP19A1—Metabolism—NDUFA12—bone cancer	0.000185	0.00215	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—RB1—bone cancer	0.000185	0.00214	CbGpPWpGaD
Levonorgestrel—Nervous system disorder—Doxorubicin—bone cancer	0.000184	0.00135	CcSEcCtD
Levonorgestrel—Insomnia—Epirubicin—bone cancer	0.000184	0.00135	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—MDM2—bone cancer	0.000183	0.00212	CbGpPWpGaD
Levonorgestrel—Skin disorder—Doxorubicin—bone cancer	0.000183	0.00134	CcSEcCtD
Levonorgestrel—ESR1—Regulation of Telomerase—EGFR—bone cancer	0.000182	0.00212	CbGpPWpGaD
Levonorgestrel—Hyperhidrosis—Doxorubicin—bone cancer	0.000182	0.00133	CcSEcCtD
Levonorgestrel—Dyspnoea—Epirubicin—bone cancer	0.000181	0.00133	CcSEcCtD
Levonorgestrel—Somnolence—Epirubicin—bone cancer	0.000181	0.00133	CcSEcCtD
Levonorgestrel—Anorexia—Doxorubicin—bone cancer	0.000179	0.00131	CcSEcCtD
Levonorgestrel—Dyspepsia—Epirubicin—bone cancer	0.000179	0.00131	CcSEcCtD
Levonorgestrel—ESR1—Signaling by ERBB4—KIT—bone cancer	0.000178	0.00207	CbGpPWpGaD
Levonorgestrel—Gastrointestinal pain—Methotrexate—bone cancer	0.000178	0.0013	CcSEcCtD
Levonorgestrel—PGR—Gene Expression—NR1I2—bone cancer	0.000177	0.00206	CbGpPWpGaD
Levonorgestrel—Decreased appetite—Epirubicin—bone cancer	0.000177	0.0013	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Epirubicin—bone cancer	0.000175	0.00129	CcSEcCtD
Levonorgestrel—Fatigue—Epirubicin—bone cancer	0.000175	0.00129	CcSEcCtD
Levonorgestrel—Pain—Epirubicin—bone cancer	0.000174	0.00127	CcSEcCtD
Levonorgestrel—Constipation—Epirubicin—bone cancer	0.000174	0.00127	CcSEcCtD
Levonorgestrel—Urticaria—Methotrexate—bone cancer	0.000173	0.00127	CcSEcCtD
Levonorgestrel—Abdominal pain—Methotrexate—bone cancer	0.000172	0.00126	CcSEcCtD
Levonorgestrel—Body temperature increased—Methotrexate—bone cancer	0.000172	0.00126	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000171	0.00126	CcSEcCtD
Levonorgestrel—Insomnia—Doxorubicin—bone cancer	0.00017	0.00125	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—BRAF—bone cancer	0.000168	0.00195	CbGpPWpGaD
Levonorgestrel—Dyspnoea—Doxorubicin—bone cancer	0.000168	0.00123	CcSEcCtD
Levonorgestrel—Somnolence—Doxorubicin—bone cancer	0.000167	0.00123	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Epirubicin—bone cancer	0.000166	0.00122	CcSEcCtD
Levonorgestrel—Dyspepsia—Doxorubicin—bone cancer	0.000166	0.00121	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—RB1—bone cancer	0.000165	0.00192	CbGpPWpGaD
Levonorgestrel—Decreased appetite—Doxorubicin—bone cancer	0.000164	0.0012	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—EGFR—bone cancer	0.000163	0.0019	CbGpPWpGaD
Levonorgestrel—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000162	0.00119	CcSEcCtD
Levonorgestrel—Fatigue—Doxorubicin—bone cancer	0.000162	0.00119	CcSEcCtD
Levonorgestrel—Urticaria—Epirubicin—bone cancer	0.000161	0.00118	CcSEcCtD
Levonorgestrel—Pain—Doxorubicin—bone cancer	0.000161	0.00118	CcSEcCtD
Levonorgestrel—Constipation—Doxorubicin—bone cancer	0.000161	0.00118	CcSEcCtD
Levonorgestrel—Body temperature increased—Epirubicin—bone cancer	0.000161	0.00118	CcSEcCtD
Levonorgestrel—Abdominal pain—Epirubicin—bone cancer	0.000161	0.00118	CcSEcCtD
Levonorgestrel—Hypersensitivity—Methotrexate—bone cancer	0.00016	0.00117	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—JUN—bone cancer	0.000159	0.00185	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.000158	0.00183	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—MDM2—bone cancer	0.000157	0.00183	CbGpPWpGaD
Levonorgestrel—Asthenia—Methotrexate—bone cancer	0.000156	0.00114	CcSEcCtD
Levonorgestrel—AR—SIDS Susceptibility Pathways—JUN—bone cancer	0.000155	0.0018	CbGpPWpGaD
Levonorgestrel—Gastrointestinal pain—Doxorubicin—bone cancer	0.000154	0.00113	CcSEcCtD
Levonorgestrel—Pruritus—Methotrexate—bone cancer	0.000154	0.00113	CcSEcCtD
Levonorgestrel—CYP19A1—Metabolism—NT5C3A—bone cancer	0.000153	0.00178	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.000152	0.00176	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—FUS—bone cancer	0.00015	0.00174	CbGpPWpGaD
Levonorgestrel—Hypersensitivity—Epirubicin—bone cancer	0.00015	0.0011	CcSEcCtD
Levonorgestrel—ESR1—AP-1 transcription factor network—TP53—bone cancer	0.00015	0.00174	CbGpPWpGaD
Levonorgestrel—Urticaria—Doxorubicin—bone cancer	0.000149	0.0011	CcSEcCtD
Levonorgestrel—Body temperature increased—Doxorubicin—bone cancer	0.000149	0.00109	CcSEcCtD
Levonorgestrel—Abdominal pain—Doxorubicin—bone cancer	0.000149	0.00109	CcSEcCtD
Levonorgestrel—Diarrhoea—Methotrexate—bone cancer	0.000149	0.00109	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.000146	0.0017	CbGpPWpGaD
Levonorgestrel—Asthenia—Epirubicin—bone cancer	0.000146	0.00107	CcSEcCtD
Levonorgestrel—Pruritus—Epirubicin—bone cancer	0.000144	0.00105	CcSEcCtD
Levonorgestrel—Dizziness—Methotrexate—bone cancer	0.000144	0.00105	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—MDM2—bone cancer	0.000141	0.00164	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—MDM2—bone cancer	0.00014	0.00163	CbGpPWpGaD
Levonorgestrel—Diarrhoea—Epirubicin—bone cancer	0.000139	0.00102	CcSEcCtD
Levonorgestrel—Hypersensitivity—Doxorubicin—bone cancer	0.000139	0.00102	CcSEcCtD
Levonorgestrel—Vomiting—Methotrexate—bone cancer	0.000138	0.00101	CcSEcCtD
Levonorgestrel—Rash—Methotrexate—bone cancer	0.000137	0.001	CcSEcCtD
Levonorgestrel—Dermatitis—Methotrexate—bone cancer	0.000137	0.001	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—JUN—bone cancer	0.000137	0.00159	CbGpPWpGaD
Levonorgestrel—Headache—Methotrexate—bone cancer	0.000136	0.000998	CcSEcCtD
Levonorgestrel—AR—Gene Expression—NR1I2—bone cancer	0.000135	0.00157	CbGpPWpGaD
Levonorgestrel—Asthenia—Doxorubicin—bone cancer	0.000135	0.00099	CcSEcCtD
Levonorgestrel—Dizziness—Epirubicin—bone cancer	0.000134	0.000986	CcSEcCtD
Levonorgestrel—Pruritus—Doxorubicin—bone cancer	0.000133	0.000976	CcSEcCtD
Levonorgestrel—PGR—Signaling Pathways—GRM4—bone cancer	0.000133	0.00154	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—RGS1—bone cancer	0.000133	0.00154	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	0.000132	0.00153	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—EIF2S1—bone cancer	0.000131	0.00152	CbGpPWpGaD
Levonorgestrel—Vomiting—Epirubicin—bone cancer	0.000129	0.000948	CcSEcCtD
Levonorgestrel—Nausea—Methotrexate—bone cancer	0.000129	0.000946	CcSEcCtD
Levonorgestrel—Diarrhoea—Doxorubicin—bone cancer	0.000129	0.000944	CcSEcCtD
Levonorgestrel—Rash—Epirubicin—bone cancer	0.000128	0.00094	CcSEcCtD
Levonorgestrel—Dermatitis—Epirubicin—bone cancer	0.000128	0.000939	CcSEcCtD
Levonorgestrel—Headache—Epirubicin—bone cancer	0.000127	0.000934	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—EGFR—bone cancer	0.000125	0.00145	CbGpPWpGaD
Levonorgestrel—Dizziness—Doxorubicin—bone cancer	0.000124	0.000912	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—JUN—bone cancer	0.000122	0.00142	CbGpPWpGaD
Levonorgestrel—Nausea—Epirubicin—bone cancer	0.000121	0.000885	CcSEcCtD
Levonorgestrel—Vomiting—Doxorubicin—bone cancer	0.00012	0.000877	CcSEcCtD
Levonorgestrel—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	0.000119	0.00138	CbGpPWpGaD
Levonorgestrel—Rash—Doxorubicin—bone cancer	0.000119	0.00087	CcSEcCtD
Levonorgestrel—Dermatitis—Doxorubicin—bone cancer	0.000118	0.000869	CcSEcCtD
Levonorgestrel—Headache—Doxorubicin—bone cancer	0.000118	0.000864	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.000117	0.00136	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—GRM1—bone cancer	0.000115	0.00134	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—EZH2—bone cancer	0.000114	0.00132	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.000113	0.00131	CbGpPWpGaD
Levonorgestrel—Nausea—Doxorubicin—bone cancer	0.000112	0.000819	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—PTGS2—bone cancer	0.000108	0.00125	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—EGFR—bone cancer	0.000108	0.00125	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—TP53—bone cancer	0.000105	0.00122	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—NR1I2—bone cancer	0.000104	0.00121	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	0.000104	0.0012	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	0.000101	0.00118	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—EIF2S1—bone cancer	9.97e-05	0.00116	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—EGFR—bone cancer	9.63e-05	0.00112	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—EGFR—bone cancer	9.58e-05	0.00111	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—TP53—bone cancer	9.03e-05	0.00105	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	8.7e-05	0.00101	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—EZH2—bone cancer	8.66e-05	0.00101	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—SMO—bone cancer	8.12e-05	0.000943	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—TP53—bone cancer	8.09e-05	0.000939	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	7.98e-05	0.000927	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—GRM4—bone cancer	7.8e-05	0.000906	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—RGS1—bone cancer	7.8e-05	0.000906	CbGpPWpGaD
Levonorgestrel—CYP3A4—Biological oxidations—GSTP1—bone cancer	7.7e-05	0.000895	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—EIF2S1—bone cancer	7.68e-05	0.000892	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	7.6e-05	0.000882	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—GNA11—bone cancer	7.42e-05	0.000862	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—ATF1—bone cancer	6.9e-05	0.000802	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—GRM1—bone cancer	6.76e-05	0.000785	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—IL3—bone cancer	6.73e-05	0.000782	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—ENO2—bone cancer	6.71e-05	0.00078	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	6.7e-05	0.000778	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—EZH2—bone cancer	6.67e-05	0.000775	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—DHFR—bone cancer	6.23e-05	0.000723	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—GNA11—bone cancer	5.82e-05	0.000676	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—TGFBR2—bone cancer	5.76e-05	0.000669	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—IGF1R—bone cancer	5.42e-05	0.000629	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—NDUFA12—bone cancer	5.4e-05	0.000627	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—CYP3A4—bone cancer	5.28e-05	0.000613	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	5.25e-05	0.00061	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—SMO—bone cancer	4.76e-05	0.000553	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—GSTP1—bone cancer	4.51e-05	0.000524	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—NT5C3A—bone cancer	4.47e-05	0.00052	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—GNA11—bone cancer	4.36e-05	0.000506	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—ATF1—bone cancer	4.05e-05	0.000471	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—IL3—bone cancer	3.95e-05	0.000459	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—KIT—bone cancer	3.93e-05	0.000456	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—BRAF—bone cancer	3.69e-05	0.000429	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TGFBR2—bone cancer	3.38e-05	0.000392	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—IGF1R—bone cancer	3.18e-05	0.000369	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MDM2—bone cancer	3.09e-05	0.000359	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—JUN—bone cancer	2.69e-05	0.000312	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MMP9—bone cancer	2.62e-05	0.000304	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PTGS2—bone cancer	2.34e-05	0.000272	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—KIT—bone cancer	2.31e-05	0.000268	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—BRAF—bone cancer	2.17e-05	0.000252	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—EGFR—bone cancer	2.11e-05	0.000246	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ENO2—bone cancer	1.96e-05	0.000228	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—DHFR—bone cancer	1.82e-05	0.000211	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MDM2—bone cancer	1.82e-05	0.000211	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—TP53—bone cancer	1.78e-05	0.000206	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GNA11—bone cancer	1.7e-05	0.000197	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—JUN—bone cancer	1.58e-05	0.000183	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MMP9—bone cancer	1.54e-05	0.000178	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GSTP1—bone cancer	1.32e-05	0.000153	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—EGFR—bone cancer	1.24e-05	0.000144	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TP53—bone cancer	1.04e-05	0.000121	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PTGS2—bone cancer	6.82e-06	7.93e-05	CbGpPWpGaD
